A Phase 3 interventional study of Metformin and Insulin in Gestational Diabetes Mellitus in Pregnancy, sponsored by Services Institute of Medical Sciences, Pakistan. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-27.
Sponsored by Services Institute of Medical Sciences, Pakistan · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.
Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 7th largest by enrollment, is one of 4 that started in 2016, is one of 12 in phase 3, and was the 27th registered.
877 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.
Browse Diabetes, Gestational studies →4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–50 · Women only
Anna Stanhewicz, PhD · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+ · Women only
Assiut University
Ages 18–40 · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 134 Diabetes, Gestational studies recruiting now, 62 (46%) set no upper age limit and 70 (52%) stop at 75 or younger; 13 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 16 · Phase 4 13
First in 2002; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 278 is above the median of 110 across 564 interventional studies indexed under Diabetes, Gestational.
Median enrollment 112 across the 39 interventional studies. Of the 23 that completed or were terminated, 7 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 39 has an industry lead sponsor. The 10 most frequent:
Services Institute of Medical Sciences, Pakistan is the lead sponsor of 34 studies on the registry; 7 are open to participants now.
Services Institute of Medical Sciences, Pakistan has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
1 of the studies testing metformin in Diabetes, Gestational that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948825George Washington UniversityEffectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies testing metformin in Diabetes, Gestational, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gestational diabetic mellitus (GDM) patients randomised to metformin or insulin group.Aim was to achieve blood sugar levels of Blood sugar fasting (BSF) \<5.3 mmol/l and 1 hour post meal\<7.8mmol/l. Both groups were followed till delivery and outcome studied.
75 gm Oral Glucose Tolerance Test (OGTT) was done in pregnant patients. Blood sugar fasting(BSF) > 5.5 mmol/l \& 2 hours postprandial >7.8 mmol/l was labelled as GDM. They were randomised to metformin or insulin group. Those assigned to metformin group were started metformin 500mg twice daily \& increased until 2500mg depending on the blood sugar levels. Aim was to achieve blood sugar levels of BSF \<5.3 mmol/l and 1 hour post meal\<7.8mmol/l. If blood sugar levels were not controlled, insulin was added. The insulin group was given 3 injections of regular insulin \& one intermediate acting insulin injection at night subcutaneously. Both groups were followed till delivery and outcome studied
Inclusion Criteria:•
Exclusion Criteria:
Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
Drug: Metformin
Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
Drug: Insulin
metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery
Also known as: Glucophage
The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
Also known as: Humulin R U 100 and Humulin N
maternal glycemic control
Maternal glycemic control was measured by blood sugar levels
Time frame: From time of randomisation till 40 weeks
Fetal macrosomia
Birth weight more than 4kg
Time frame: at birth
Apgar score
\<7 at 5min
Time frame: at birth
Neonatal intensive care unit (NICU) stay
Admitted to NICU
Time frame: >24 hours after birth
Perinatal death
Fetal or neonatal death within 7 days
Time frame: 7 days of delivery
mode of delivery
Lower segment cesarean section , Spontaneous Vaginal Delivery, Instrumental delivery
Time frame: at delivery
Neonatal hypoglycemia
Neonatal blood sugar was checked at birth and if \<2.2mmol/l, was labelled
Time frame: at birth
Ran from Feb 2016 to primary completion in Jun 2017, 16 months.
Of 14 phase 3 interventional studies under Diabetes, Gestational, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Services Institute of Medical Sciences, Pakistan